Apremilast

Apremilast
Clinical data
Pronunciation/əˈprɛmɪlæst/ ə-PREM-i-last
Trade namesOtezla, others
Other namesCC-10004
AHFS/Drugs.comMonograph
MedlinePlusa614022
License data
Pregnancy
category
Routes of
administration		By mouth
ATC code
Legal status
Legal status
Pharmacokinetic data
Bioavailability73%;[8] Tmax = ~2.5 hours
Protein bindingc. 68%[8]
MetabolismLiver (CYP3A4, with minor contributions from CYP2A6, CYP1A2)[8]
MetabolitesO-desmethylapremilast glucuronide (and others)[9]
Elimination half-life6–9 hours[8]
ExcretionUrine (58%), faeces (39%)[8]
Identifiers
  • N-{2-[(1S)-1-(3-Ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl}acetamide
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.234.786 Edit this at Wikidata
Chemical and physical data
FormulaC22H24N2O7S
Molar mass460.50 g·mol−1
3D model (JSmol)
  • O=S(=O)(C)C[C@H](c1ccc(OC)c(OCC)c1)N3C(=O)c2cccc(c2C3=O)NC(=O)C
  • InChI=1S/C22H24N2O7S/c1-5-31-19-11-14(9-10-18(19)30-3)17(12-32(4,28)29)24-21(26)15-7-6-8-16(23-13(2)25)20(15)22(24)27/h6-11,17H,5,12H2,1-4H3,(H,23,25)/t17-/m1/s1
  • Key:IMOZEMNVLZVGJZ-QGZVFWFLSA-N

Apremilast, sold under the brand name Otezla among others, is a medication for the treatment of certain types of psoriasis and psoriatic arthritis.[4] The drug acts as a selective inhibitor of the enzyme phosphodiesterase 4 (PDE4).[4] It is taken by mouth.[4]

  1. ^ a b "AusPAR: Apremilast". Therapeutic Goods Administration (TGA).
  2. ^ "Prescription medicines: registration of new chemical entities in Australia, 2015". Therapeutic Goods Administration (TGA). 21 June 2022. Retrieved 10 April 2023.
  3. ^ "Otezla 30 mg Film-Coated Tablets – Summary of Product Characteristics (SmPC)". (emc). 15 April 2020. Retrieved 19 April 2020.
  4. ^ a b c d Cite error: The named reference Otezla FDA label was invoked but never defined (see the help page).
  5. ^ "Otezla- apremilast kit; Otezla- apremilast tablet, film coated". DailyMed. 5 February 2021. Retrieved 17 October 2024.
  6. ^ Cite error: The named reference Otezla EPAR was invoked but never defined (see the help page).
  7. ^ Cite error: The named reference Apremilast Accord EPAR was invoked but never defined (see the help page).
  8. ^ a b c d e "Otezla (aprelimast) dosing, indications, interactions, adverse effects, and more". Medscape Reference. WebMD. Retrieved 28 March 2014.
  9. ^ Cite error: The named reference AC was invoked but never defined (see the help page).